Interim Phase 2 Aranesp(R) Data Suggest Major Response after 27/28 Weeks of Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS) Read more about Interim Phase 2 Aranesp(R) Data Suggest Major Response after 27/28 Weeks of Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS)
Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies Read more about Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies
ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO Read more about ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO
Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology Read more about Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology
Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 26 Percent to 91 Cents; First Quarter 2006 GAAP Earnings Per Share Increased 22 Percent to 82 Cents Read more about Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 26 Percent to 91 Cents; First Quarter 2006 GAAP Earnings Per Share Increased 22 Percent to 82 Cents
Amgen Files with ITC Against Roche's Importation of peg-EPO Read more about Amgen Files with ITC Against Roche's Importation of peg-EPO
2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto Rico Read more about 2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto Rico
Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients Read more about Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Amgen Announces Webcast of First Quarter Financial Results Read more about Amgen Announces Webcast of First Quarter Financial Results
Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty Read more about Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
